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A B S T R A C T
We report a case of a patient with lymphocutaneous sporotrichosis in the right upper limb. The fungus was
identified as Sporothrix schenckii senso stricto by calmodulin gene sequencing. The initial treatment was itra-
conazole (200 mg/day), but in vitro antifungal susceptibility demonstrated high resistant to this and another six
antifungals, with exception to terbinafine. The lesions did not regress with itraconazole treatment. Thus,
500 mg/day of terbinafine was prescribed and clinical cure was obtained after four months
1. Introduction
Sporotrichosis is a subacute or chronic infection caused by di-
morphic fungi of the Sporothrix schenckii complex, which include: S.
schenckii senso stricto, S. brasiliensis, S. globosa and S. luriei. Rarely
species of the Sporothrix pallida complex may be the cause of the disease
[1]. The main route of transmission of sporotrichosis is percutaneous,
through traumatisms and bruises with contaminated surfaces (woods,
thorns, splinters) [2–4]. Although it has a universal geographical dis-
tribution, sporotrichosis predominates in southern Africa, America
(mainly in Brazil, Peru, Colombia, Guatemala, Mexico and the United
States), Asia (Japan, India, China) and Oceania (Australia) [2,4,5]. In
the state of Rio de Janeiro, Brazil, outbreaks of human sporotrichosis
involving the transmission of the disease through contact with bites and
scratches of infected cats are described. Other Brazilian states of greater
prevalence are Rio Grande do Sul and São Paulo, mainly in men, adults,
involved in activities that facilitate exposure to the etiological agent,
such as rural workers [3,4,6].
Although some studies show differences in the susceptibility profile
to antifungal in different isolates of the same species of Sporothrix [6,7]
little is known about the in vitro-in vivo correlation for determination of
breakpoints for evaluation of antifungal sensitivity profile of the iso-
lates of the genus [6]. This report presents a case of sporotrichosis in
which the susceptibility test was important for the success of the
therapy of a sporotrichosis caused by S. schenckii senso stricto.
2. Case
In March 2016, a male 63 years old patient, farmer, previously
treated at the dermatology department of Santa Clara Hospital (posto
G) in the Santa Casa de Misericórdia Hospital Complex of Porto Alegre,
presenting, for more than 3 months, a verrucous plaque on the back of
the right hand. In addition to papules and erythematous-purpura no-
dules, with suppurative tendency, in the forearm and ipsilateral arm,
following ascending lymphatic path, suggesting sporotrichosis (Fig. 1A-
B). Day zero, admission of the patient, was considered the first day he
came to the hospital to seek help after 3 months of ineffective treat-
ment. The patient reported that he had not previously used antifungal
medication for the treatment of possible infection. On the same day of
the consultation, a sample of purulent material from the patient's le-
sions for direct and cultural mycological examination was collected.
Direct mycological examination was negative for the presence of yeast
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cells. However, due to clinical suspicion, treatment with itraconazole
200 mg/day was initiated. Five days after day zero, in the cultural ex-
amination with cultivation on Sabouraud dextrose agar at 25 °C, there
was growth of whitish filamentous colony which, on microscopy, pre-
sented hyphae with conidiophore characteristic of Sporothrix sp., con-
firming the previous diagnosis. For identification at the species level,
total genomic DNA was isolated using Power Soil DNA Isolation Kit
(Mobio, USA). Partial sequencing of the nuclear calmodulin gene was
performed with primers CL1 and CL2A, as described by Stopiglia et al.
[6]. The PCR product was purified using the ExoSAP-IT (Affymetrix,
USA) and sequenced in the ABIPRISM 3100 Genetic Analyzer (Applied
Biosystems), according to the manufacturer's instructions. The sequence
was compared with sequences of type strains reported in GenBank using
the Basic Local Alignment Search Tool (BLAST) algorithm. The fungal
was confirmed as Sporothrix schenckii, since it presented sequence
identity at 97% and coverage at 97% with the type strain of this species
CBS 359.36T. This strain was added to GenBank as number MF943129.
An antifungal susceptibility test was requested, since the infection
presented extensive cutaneous involvement. In this test, the minimum
inhibitory concentration (MIC) of seven antifungal agents was eval-
uated by the 96-well plate microdilution method according to protocol
M38-A2 do Clinical & Laboratory Standards Institute (CLSI) [8]. The MICs
(μg / ml) obtained were: terbinafine (0.25); posaconazole (2.0); keto-
conazole (4.0); amphotericin B (8.0); itraconazole (16.0); voriconazole
(> 16.0); fluconazole (> 64.0). In view of the possible in vitro re-
sistance of the isolate to itraconazole and the high MICs of all other
antifungal agents, except for terbinafine, the patient was reassessed
after 48 days of treatment with itraconazole. As the patient showed no
signs of clinical improvement, itraconazole was replaced by terbinafine
500 mg/day. After 4 months of treatment with terbinafine, the patient
was discharged with clinical cure of the disease, presenting slight re-
sidual atrophy in the areas of previous skin lesions (Fig. 1C-D) one year
after the end of treatment, there was no recurrence of the disease.
3. Discussion
Sporothrix schenkii was identified more than a century ago [4] and is
considered as the only species that causes the disease until the ap-
pearance of identification through the sequencing of regions of the
fungus DNA, such as partial calmodulin gene, that allows the identifi-
cation of the different species of the Sporothrix genus [1,6].
In the direct mycological examination, the yeasts of Sporothrix spp.
are rarely observed. Thus, cultural mycological examination is the re-
ference method for the diagnostic confirmation of sporotrichosis
[4,5,9], with the identification of the fungus generally limited to genus
level in clinical practice. However, species-level identification is be-
coming important for the determination of possibly resistant isolates,
since epidemiological cutoff values (ECVs) of MICs of some antifungals
have been stipulated for the most prevalent species, S. schenckii and S.
brasiliensis [7].
S. schenckii senso stricto has universal geographical distribution
[3,4] and the other species are related to different geographical origins
[6]. In Brazil, S. brasiliensis has been reported as a more frequent species
[3,4,10,11]. However, these studies are linked to isolates from epidemic
outbreaks with zoonotic transmission from the metropolitan region of
the state of Rio de Janeiro. In Rio Grande do Sul, S. schenckii senso
stricto, which was the species that caused the disease in the present
patient, has been considered the most frequent species in 92.5% of
sporotrichosis cases [6]. In addition, other clinical-epidemiological data
from this report are compatible with the regional literature, since the
patient is an adult male, a farmer, and had upper limb lesions in the
clinical form of lymphobuccal disease, which is the site and most
common form of the disease [4,9,12,13].
The treatment of choice for strict cutaneous sporotrichosis and
lymphobutanation in many countries is itraconazole 200 mg/day for
3–6 months. This antifungal can also be used in the disseminated form
of the disease [14]. For cutaneous forms, alternatively, oral potassium
iodide solution could be used, since it is considered a first-choice drug
in developing countries, due to its high efficiency, low cost and safety
profile [2,15,16]. However, the occurrence of adverse effects with io-
dine (such as gastrointestinal intolerance and metallic taste) and the
more convenient dosage of more modern drugs represent some of the
factors that limit its use [17]. In this case, a recent history of treatment
for “bowel lesions” reported by the patient beyond the convenience of
use, itraconazole was initially prescribed. Subsequently, we knew that
the lesions were benign intestinal tumors.
Despite frequent non-solicitation of antifungal susceptibility tests in
clinical practice, studies demonstrate variable results of antifungal
susceptibilities among isolates of the same species of Sporothrix
[6,7,11,18]. Therefore, it is important to perform a susceptibility test to
aid in the choice of treatment, especially in cases refractory to initial
treatment or in more severe forms of the disease [18]. For S. schenckii
senso stricto, 9.8% of clinical isolates from various regions of the world
[7] and 6.5% of Brazilian isolates [6] had MICs equal to or greater than
4 μg/mL for itraconazole, considered possibly resistant, based on ECV
of 2 μg/mL for itraconazole [7].
In a study by Espinel-Ingroff et al. [7], terbinafine had its ECV sti-
pulated at 0.12 μg/mL for S. brasiliensis, but for S. schenckii senso
stricto, no ECV was stipulated, since the data were considered in-
sufficient. The present study shows that MIC of 0.25 μg/mL in vitro led
Fig. 1. Lesions of sporotrichosis, containing nodule
following the ascending lymphatic path (A) with
verrucous plaque in right hand, initial site of infec-
tion (B); After four months of treatment with terbi-
nafine (500 mg/day), showing scars of the lesions (C,
D).
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to cure of the disease in 4 months of terbinafine monotherapy in the
total dosage of 500 mg/day. A case report of sporotrichosis with failed
therapy using itraconazole and success with terbinafine relating to in
vitro results for both antifungal was previously published [19]. How-
ever, the species was not identified at the species level and also pre-
sented MIC lower than the present study for terbinafine. Therefore, the
results of the present study may help to determine the ECV of terbi-
nafine in S. schenckii senso stricto, as well as to help in decision making
in cases similar to these studies, in which high MICs of the antifungal
were obtained, except to the MIC of terbinafine [19].
In addition to case reports evidencing the success of terbinafine in
lymphocutaneous sporotrichosis [19,20], the clinical trial of Frances-
coni et al. [12] compared the use of itraconazole 100 mg/day with
terbinafine 250 mg/day in the treatment of sporotrichosis in fixed cu-
taneous and lymphocutaneous forms in a total of 304 patients, with no
statistically significant difference in efficacy between terbinafine and
itraconazole (92.7% and 92%, respectively). Furthermore, the fre-
quency of relapses was similar in both treatments (less than 2%). In
addition to the clinical results equivalent to itraconazole observed,
terbinafine has less drugs interactions than itraconazole [12], making it
preferable to use in elderly patients, since they generally use many
medications of continuous use [19].
In this case, the antifungal susceptibility test prevented an in-
effective treatment of sporotrichosis with itraconazole to continue,
which reduced time to resolution of the disease, in addition to possible
future drug interactions and treatment costs. The use of terbinafine,
although still restricted, was based on the antifungal susceptibility test
of the patient isolate and was supported by the success in the therapy
with terbinafine in clinical trials and case reports found in the litera-
ture, which ensured the safety of the clinical staff in altering the
therapy of the patient, being successful in this clinical decision making.
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